

Table S2 Baseline clinical characteristics of 22 patients treated with other BsAb

| Characteristics | Value |
|---|--------------|
| Median age, yr (range) | 60 (43-74) |
| Male sex, no. (%) | 13 (59.1) |
| ECOG performance score, no. (%) | |
| 0 | 19 (86.4) |
| 1 | 3 (13.6) |
| Ann Arbor stage, no. (%) | |
| I | 1 (4.5) |
| II | 1 (4.5) |
| III | 2 (9.1) |
| IV | 18 (81.8) |
| Subtype, no. (%) | |
| DLBCL NOS | 12 (54.5) |
| Transformed large B cell lymphoma | 8 (36.4) |
| MZL | 1 (4.5) |
| MCL | 1 (4.5) |
| Bulky disease, no. (%) | |
| >6cm | 10 (45.5) |
| >10cm | 4 (18.2) |
| Previous lines of therapy, no. (%) | |
| Median lines (range) | 2 (1-5) |
| ≥3 previous lines | 9 (40.9) |
| Previous therapy for lymphoma, no. (%) | |
| Anti-CD20 antibody | 22 (100) |
| CAR-T therapy | 5 (22.7) |
| ASCT | 3 (13.6) |
| Relapsed or refractory status, no. (%) | |
| Refractory to any previous therapy | 10 (45.5) |
| Refractory to last previous therapy | 12 (54.5) |
| Primary refractory | 8 (36.4) |
| Refractory to previous CAR-T therapy | 1 (4.5) |

CAR-T, Chimeric antigen receptor-T; DLBCL, Diffuse large B cell lymphoma; MCL, Mantle cell lymphoma; ASCT, Autologous stem-cell transplantation; MZL, Marge zone lymphoma.